<DOC>
	<DOCNO>NCT03013218</DOCNO>
	<brief_summary>A phase 1 , dose escalation study ALX148 patient advance solid tumor lymphoma</brief_summary>
	<brief_title>A Study ALX148 Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>This phase 1 clinical study ( AT148001 ) open-label , multi-center , multiple-dose , dose-escalation , safety , PK , PD study ALX148 . The phase 1 protocol 2 part : single agent dose escalation phase ( Part 1 ) combination therapy phase ( Part 2 ) . Part 2 include initial dose escalation portion follow dose expansion portion . Approximately 110 adult patient expect enrolled study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological cytological diagnosis advanced/metastatic solid tumor malignancy resistant standard therapy standard therapy available ; relapse refractory NonHodgkin lymphoma standard therapy available . Adequate Bone Marrow Function . Adequate Renal &amp; Liver Function . Adequate Performance Status Patients know symptomatic CNS metastases lepotomeningeal disease require steroid . Previous highdose chemotherapy require stem cell rescue . Prior irradiation &gt; 25 % bone marrow . Prior treatment CD47 signal regulatory protein ( SIRP ) alpha target agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>CD47</keyword>
	<keyword>SIRPÎ±</keyword>
	<keyword>ALX148</keyword>
</DOC>